Double-blind Clinical Trials of Probiotic Products in Oral Health.
NCT ID: NCT04289337
Last Updated: 2020-02-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
130 participants
INTERVENTIONAL
2019-10-21
2019-12-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Combined probiotics (1)
Combined Lactobacillus salivarius subsp. salicinius AP-32, Bifidobacterium animalis subsp. lactis CP-9 and Lactobacillus paracasei ET-66.
Combined probiotics (1)
Subjects used one oral combined probiotics (1) tablet each morning, noon, and evening for 4 weeks.
Combined probiotics (2)
Combined Lactobacillus salivarius subsp. salicinius AP-32, Lactobacillus plantarum LPL28 and Lactobacillus paracasei ET-66.
Combined probiotics (2)
Subjects used one oral combined probiotics (2) tablet each morning, noon, and evening for 4 weeks.
Combined heat-killed probiotics (1)
Combined heat-killed Lactobacillus salivarius subsp. salicinius AP-32, Bifidobacterium animalis subsp. lactis CP-9 and Lactobacillus paracasei ET-66.
Combined heat-killed probiotics (1)
Subjects used one oral combined heat-killed probiotics (1) tablet each morning, noon, and evening for 4 weeks.
Combined heat-killed probiotics (2)
Combined heat-killed Lactobacillus salivarius subsp. salicinius AP-32 and Lactobacillus paracasei ET-66.
Combined heat-killed probiotics (2)
Subjects used one oral combined heat-killed probiotics (2) tablet each morning, noon, and evening for 4 weeks.
Probiotic metabolites
Combined Lactobacillus salivarius subsp. salicinius AP-32, Lactobacillus plantarum LPL28 and Lactobacillus paracasei ET-66 metabolites.
Probiotic metabolites
Subjects used one oral probiotic metabolites tablet each morning, noon, and evening for 4 weeks.
Placebo
Does not contain probiotics, heat-killed probiotics and related metabolites.
Placebo
Subjects used one oral placebo tablet each morning, noon, and evening for 4 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Combined probiotics (1)
Subjects used one oral combined probiotics (1) tablet each morning, noon, and evening for 4 weeks.
Combined probiotics (2)
Subjects used one oral combined probiotics (2) tablet each morning, noon, and evening for 4 weeks.
Combined heat-killed probiotics (1)
Subjects used one oral combined heat-killed probiotics (1) tablet each morning, noon, and evening for 4 weeks.
Combined heat-killed probiotics (2)
Subjects used one oral combined heat-killed probiotics (2) tablet each morning, noon, and evening for 4 weeks.
Probiotic metabolites
Subjects used one oral probiotic metabolites tablet each morning, noon, and evening for 4 weeks.
Placebo
Subjects used one oral placebo tablet each morning, noon, and evening for 4 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* More than 10\^5 Streptococcus mutans (CFU/mL) of saliva.
Exclusion Criteria
* Subject has major illness.
20 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Glac Biotech Co., Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hsieh-Hsun Ho
R.D. Manager Doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hsieh-Hsun Ho, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Glac Biotech Co., Ltd
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Glac Biotech Co., Ltd
Tainan City, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CS19052
Identifier Type: -
Identifier Source: org_study_id